HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
m9nLcPv3r86SVULN